XOMA Declares Quarterly Preferred Stock Dividends
20 12월 2023 - 9:30PM
XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today
announced its Board of Directors has authorized the following cash
dividends to holders of XOMA’s Series A and Series B Cumulative
Preferred Stock:
Holders of the 8.625% Series A Cumulative Perpetual Preferred
Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to
$0.53906 per share.
Holders of depositary shares, each representing 1/1000 of a
share of XOMA’s 8.375% Series B Cumulative Perpetual Preferred
Stock (Nasdaq: XOMAO), shall receive a cash dividend equal to
$0.52344 per depositary share.
The preferred dividends will be paid on or about January 16,
2024, to respective holders of record at the close of business on
January 3, 2024.
About XOMA CorporationXOMA is a biotechnology
royalty aggregator playing a distinctive role in helping biotech
companies achieve their goal of improving human health. XOMA
acquires the potential future economics associated with
pre-commercial therapeutic candidates that have been licensed to
pharmaceutical or biotechnology companies. When XOMA acquires
the future economics, the seller receives non-dilutive,
non-recourse funding they can use to advance their internal drug
candidate(s) or for general corporate purposes. The Company
has an extensive and growing portfolio with more than 70 assets
(asset defined as the right to receive potential future economics
associated with the advancement of an underlying therapeutic
candidate). For more information about the Company and its
portfolio, please visit www.xoma.com.
Forward-Looking Statements/Explanatory
NotesCertain statements contained in this press release
are forward-looking statements within the meaning of Section 27A of
the Securities Act of 1933, amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. In some cases,
you can identify such forward-looking statements by terminology
such as “will” or “shall”, the negative of these terms or similar
expressions. These forward-looking statements are not a
guarantee of XOMA’s performance, and you should not place
undue reliance on such statements. These statements are based
on assumptions that may not prove accurate, and actual results
could differ materially from those anticipated due to certain risks
inherent in the biotechnology industry, including those related to
the fact that our product candidates subject to out-license
agreements are still being developed, and our licensees may require
substantial funds to continue development which may not be
available; we do not know whether there will be, or will continue
to be, a viable market for the products in which we have an
ownership or royalty interest; if the therapeutic product
candidates to which we have a royalty interest do not receive
regulatory approval, our third-party licensees will not be able to
market them, and the impact to the global economy as a result of
the COVID-19 pandemic. Other potential risks to XOMA meeting
these expectations are described in more detail in XOMA's most
recent filing on Form 10-Q and in other SEC filings. Consider
such risks carefully when considering XOMA's prospects. Any
forward-looking statement in this press release represents XOMA's
beliefs and assumptions only as of the date of this press release
and should not be relied upon as representing its views as of any
subsequent date. XOMA disclaims any obligation to update any
forward-looking statement, except as required by applicable
law.
EXPLANATORY NOTE: Any references to “portfolio” in this press
release refer strictly to milestone and/or royalty rights
associated with a basket of drug products in development. Any
references to “assets” in this press release refer strictly to
milestone and/or royalty rights associated with individual drug
products in development.
As of the date of this press release, all assets in XOMA’s
milestone and royalty portfolio, except Vabysmo® (faricimab), are
investigational compounds. Efficacy and safety have not been
established with any of these investigational assets, and there is
no guarantee that any will become commercially available.
Investor contact: |
Media contact: |
Juliane Snowden |
Kathy Vincent |
XOMA |
KV Consulting &
Management |
+1-646-438-9754 |
+1-310-403-8951 |
juliane.snowden@xoma.com |
kathy@kathyvincent.com |
XOMA Royalty (NASDAQ:XOMAO)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
XOMA Royalty (NASDAQ:XOMAO)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024